Dose escalation and dosimetry of first-in-human &#945; radioimmunotherapy with 212Pb-TCMC-trastuzumab.

Meredith, Ruby; Torgue, Julien; Shen, Sui; Fisher, Darrell R; Banaga, Eileen; Bunch, Patty; Morgan, Desiree; Fan, Jinda; Straughn, J Michael

Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.

Meredith, Ruby; Torgue, Julien; Shen, Sui; Fisher, Darrell R; Banaga, Eileen; Bunch, Patty; Morgan, Desiree; Fan, Jinda; Straughn, J Michael.

Affiliation

Meredith R; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama lobrown@uabmc.edu.
Torgue J; AREVA Med, Bethesda, Maryland; and.
Shen S; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Fisher DR; Dade Moeller Health Group, Richland, Washington.
Banaga E; AREVA Med, Bethesda, Maryland; and.
Bunch P; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Morgan D; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Fan J; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Straughn JM; Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

J Nucl Med ; 55(10): 1636-42, 2014 Oct.

Article de En | MEDLINE | ID: mdl-25157044

Sujet(s)
Mots clés

212Pb-TCMC-trastuzumab; alpha; dosimetry; radioimmunotherapy; radionuclide

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Radiométrie / Radio-isotopes du plomb / Radioimmunothérapie / Anticorps monoclonaux humanisés Type d'étude: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: J Nucl Med Année: 2014 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google